Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autosomal dominant polycystic kidney disease, possibly the least silent cause of chronic kidney disease

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Furlano, Monica|||0000-0003-1025-3901
Pain is the highest prioritized patient-reported outcome in people with autosomal dominant polycystic kidney disease (ADPKD) but it remains infrequently and inconsistently measured across countries, studies and trials. The study by El-Damanawi et al. integrated a network of ADPKD expert clinicians, pain specialists, researchers and patient representatives from the national UK PKD charity, with the aim of addressing the lack of validated ADPKD-specific pain assessment tools (APATs). The APAT designed by the authors included several pain measurement tools and was tested in ADPKD patients, although further validation through assessment in larger cohorts is needed. Establishing a standardized instrument for pain measurement will ensure that pain is measured and reported in a consistent way to inform decision-making and identify effective interventions aimed at managing pain and minimizing the impact pain has on patients with ADPKD. In this context, the APAT established by the authors is to be warmly welcomed.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Autosomal dominant polycystic kidney disease in young adults

  • Martínez, Víctor
  • Furlano, Mónica
  • Sans, Laia
  • Pulido, Lissett
  • García, Rebeca
  • Pérez Gómez, María Vanessa
  • Sánchez Rodríguez, Jinny
  • Blasco, Miquel
  • Castro Alonso, Cristina
  • Fernández Fresnedo, Gema
  • Roberto Robles, Nicolás
  • Valenzuela, María Pau
  • Naranjo Muñoz, Javier
  • Martín, Nadia
  • Pilco, Melissa
  • Agraz Pamplona, Irene
  • González Rodríguez, Juan David
  • Panizo, Nayara
  • Fraga, Gloria
  • Fernández, Loreto
  • López, María Teresa
  • Dall’Anese, Cecilia
  • Ortiz, Alberto
  • Torra, Roser
Background The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults. Methods Family history, hypertension, albuminuria, estimated glomerular filtration rate (eGFR) and imaging tests were examined in 346 young adults (18-30 years old) out of 2521 patients in the Spanish ADPKD registry (REPQRAD). A literature review searched for reports on hypertension in series with more than 50 young (age <30 years) ADPKD patients. Results The mean age of this young adult cohort was 25.24 (SD 3.72) years. The mean age at diagnosis of hypertension was 21.15 (SD 4.62) years, while in the overall REPQRAD population was aged 37.6 years. The prevalence of hypertension was 28.03% and increased with age (18-24 years, 16.8%; 25-30 years, 36.8%). Although prevalence was lower in women than in men, the age at onset of hypertension (21 years) was similar in both sexes. Mean eGFR was 108 (SD 21) mL/min/1.73 m(2), 38.0% had liver cysts and 3.45% of those studied had intracranial aneurysms. In multivariate analyses, hematuria episodes and kidney length were independent predictors of hypertension (area under the curve 0.75). The prevalence of hypertension in 22 pediatric cohorts was 20%-40%, but no literature reports on hypertension in young ADPKD adults were found. Conclusions Young adults present non-negligible ADPKD-related morbidity. This supports the need for a thorough assessment of young adults at risk of ADPKD that allows early diagnosis and treatment of hypertension. Lay Summary Impairment of renal function usually develops from the fourth decade of life in autosomal dominant polycystic kidney disease (ADPKD). However, hypertension precedes the onset of renal insufficiency. In published pediatric series, the prevalence of hypertension is 20%-40%. However, clinical information on young adults with ADPKD is scarce. We present the largest cohort of young adults (age 18-30 years) with ADPKD published to date. Prevalence of hypertension is 28% and increases with age, reaching 36.8% in the subgroup aged 25-30 years, despite normal glomerular filtration rate and albuminuria. The prevalence of hypertension is higher in males, but the mean age at diagnosis (21 years) was similar in both sexes. Young adults present non-negligible ADPKD-related morbidity. This supports the need for a thorough assessment that allows early diagnosis and treatment of hypertension, before decline of estimated glomerular filtration rate. Ambulatory blood pressure monitoring may be especially useful in this regard., 11 páginas
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel homozygous OSGEP gene pathogenic variants in two unrelated patients with Galloway-Mowat syndrome, case report and review of the literature

  • Domingo, Andrea|||0000-0003-3759-7595
  • Furlano, Monica|||0000-0003-1025-3901
  • Pybus, Marc|||0000-0002-6195-5738
  • Barraca, Daniel
  • Martínez, Ana Belén
  • Mora Muñoz, Emiliano
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
Galloway-Mowat syndrome (GAMOS) is a rare autosomal recessive disorder characterized by early-onset nephrotic syndrome and microcephaly with brain anomalies. WDR73 pathogenic variants were described as the first genetic cause of GAMOS and, very recently, four novel causative genes, OSGEP, LAGE3, TP53RK, and TPRKB, have been identified. We present the clinical and genetic characteristics of two unrelated infants with clinical suspicion of GAMOS who were born from consanguineous parents. Both patients showed a similar clinical presentation, with early-onset nephrotic syndrome, microcephaly, brain atrophy, developmental delay, axial hypotonia, and early fatality. We identified two novel likely disease-causing variants in the OSGEP gene. These two cases, in conjunction with the findings of a literature review, indicate that OSGEP pathogenic variants are associated with an earlier onset of nephrotic syndrome and shorter life expectancy than WDR73 pathogenic variants. Our findings expand the spectrum of pathogenic variants in the OSGEP gene and, taken in conjunction with the results of the literature review, suggest that the OSGEP gene should be considered the main known monogenic cause of GAMOS. Early genetic diagnosis of GAMOS is of paramount importance for genetic counseling and family planning.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MYH9-related disease, it does exist, may be more frequent than you think and requires specific therapy

  • Fernandez-Prado, Raul
  • Carriazo-Julio, Sol Maria
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
In this issue of ckj, Tabibzadeh et al. report one of the largest series of patients with MYH9 mutations and kidney disease. The cardinal manifestation of MYH9-related disease is thrombocytopenia with giant platelets. The population frequency of pathogenic MYH9 mutations may be at least 1 in 20 000. The literature abounds in misdiagnosed cases treated for idiopathic thrombocytopenic purpura with immune suppressants and even splenectomy. Additional manifestations include neurosensorial deafness and proteinuric and hematuric progressive kidney disease (at some point, it was called Alport syndrome with macrothrombocytopenia), leucocyte inclusions, cataracts and liver enzyme abnormalities, resulting in different names for different manifestation combinations (MATINS, May-Hegglin anomaly, Fechtner, Epstein and Sebastian syndromes, and deafness AD 17). The penetrance and severity of kidney disease are very variable, which may obscure the autosomal dominant inheritance. A correct diagnosis will both preclude unnecessary and potentially dangerous therapeutic interventions and allow genetic counselling and adequate treatment. Morphological erythrocyte, granulocyte and platelet abnormalities may allow the future development of high-throughput screening techniques adapted to clinical peripheral blood flow cytometers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

How genomics reclassifies diseases, the case of Alport syndrome

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ars, Elisabet|||0000-0002-4118-4358
In this issue, Matthews et al. provide a comprehensive review of published cohorts with heterozygous pathogenic variants in COL4A3 or COL4A4, documenting the wide spectrum of the disease. Due to the extreme phenotypes that patients with heterozygous pathogenic variants in COL4A3 or COL4A4 may show, the disease has been referred to in a variety of ways, including 'autosomal dominant Alport syndrome', 'thin basement membrane disease', 'thin basement membrane nephropathy', 'familial benign hematuria' and 'carriers of autosomal dominant Alport syndrome'. This confusion over terminology has prevented nephrologists from being sufficiently aware of the relevance of the entity. Nowadays, however, next-generation sequencing facilitates the diagnosis and it is becoming a relatively frequent finding in haematuric-proteinuric nephropathies of unknown origin, even in non-familial cases. There is a need to raise awareness among nephrologists about the disease in order to improve diagnosis and provide better management for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Arroyo, David|||0000-0003-4652-0311
  • D'Marco, Luis|||0000-0003-0148-891X
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Tomás, Patricia
  • Puchades, María Jesús
  • Panizo, Nayara|||0000-0002-1329-2976
  • Pantoja, Jonay
  • Montomoli, Marco|||0000-0003-1412-6352
  • Llisterri, José Luis
  • Pallarés Carratalá, Vicente|||0000-0002-2985-6078
  • Valdivielso, José Manuel|||0000-0003-1343-0184
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. We evaluated 2445 CKD patients (2010-2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221-0.808, p = 0.009). ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD. The online version contains supplementary material available at 10.1186/s12882-021-02313-1.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The 2019 and 2021 International Workshops on Alport Syndrome

  • Daga, Sergio
  • Ding, Jie
  • Savige, Judy|||0000-0002-6813-0288
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Hoefele, Julia|||0000-0002-7917-7129
  • Flinter, Frances
  • Gale, Daniel|||0000-0002-9170-1579
  • Aksenova, Marina|||0000-0002-3699-1884
  • Kai, Hirofumi
  • Perin, Laura
  • Barua, Moumita
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Miner, Jeff H.|||0000-0002-1510-8714
  • Massella, Laura|||0000-0001-5796-3965
  • Ljubanović, Danica Galešić
  • Lennon, Rachel|||0000-0001-6400-0227
  • Weinstock, Andrè B.
  • Knebelmann, Bertrand
  • Cerkauskaite, Agne
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Turner, A. Neil|||0000-0003-4547-873X
  • Baldassarri, Margherita
  • Pinto, Anna Maria|||0000-0001-6259-6901
  • Renieri, Alessandra|||0000-0002-0846-9220
In 1927 Arthur Cecil Alport, a South African physician, described a British family with an inherited form of kidney disease that affected males more severely than females and was sometimes associated with hearing loss. In 1961, the eponymous name Alport syndrome was adopted. In the late twentieth century three genes responsible for the disease were discovered: COL4A3, COL4A4, and COL4A5 encoding for the α3, α4, α5 polypeptide chains of type IV collagen, respectively. These chains assemble to form heterotrimers of type IV collagen in the glomerular basement membrane. Scientists, clinicians, patient representatives and their families, and pharma companies attended the 2019 International Workshop on Alport Syndrome, held in Siena, Italy, from October 22 to 26, and the 2021 online Workshop from November 30 to December 4. The main topics included: disease re-naming, acknowledging the need to identify an appropriate term able to reflect considerable clinical variability; a strategy for increasing the molecular diagnostic rate; genotype-phenotype correlation from monogenic to digenic forms; new therapeutics and new therapeutic approaches; and gene therapy using gene editing. The exceptional collaborative climate that was established in the magical medieval setting of Siena continued in the online workshop of 2021. Conditions were established for collaborations between leading experts in the sector, including patients and drug companies, with the aim of identifying a cure for Alport syndrome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease

  • Naranjo, Javier|||0000-0002-7004-6122
  • Furlano, Monica|||0000-0003-1025-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Pybus, Marc|||0000-0002-6195-5738
  • Ejarque, Laia
  • Cordoba, Christian|||0000-0003-4534-2760
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. Methods: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C-1E was assessed. Results: A total of 118 patients were MC 1C-1E. The algorithm developed by the European Renal Association-European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C-1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Genetic Features of Autosomal Dominant Alport Syndrome, A Cohort Study

  • Furlano, Monica|||0000-0003-1025-3901
  • Martínez, Victor
  • Pybus, Marc|||0000-0002-6195-5738
  • Arce, Yolanda
  • Crespí, Jaume|||0000-0001-7564-2479
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Domingo, Andrea|||0000-0003-3759-7595
  • Ayasreh Fierro, Nadia|||0000-0001-6436-5621
  • Benito, Silvia
  • Lorente, Laura
  • Ruíz, Patricia
  • Gonzalez, Vanesa L.
  • Arlandis, Rosa
  • Cabello, Elisa
  • Torres, Ferran|||0000-0002-7355-7913
  • Guirado, Luis|||0000-0001-5119-3912
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Rationale & Objective: Alport syndrome is a common genetic kidney disease accounting for approximately 2% of patients receiving kidney replacement therapy (KRT). It is caused by pathogenic variants in the gene COL4A3, COL4A4, or COL4A5. The aim of this study was to evaluate the clinical and genetic spectrum of patients with autosomal dominant Alport syndrome (ADAS). Study Design: Retrospective cohort study. Setting & Participants: 82 families (252 patients) with ADAS were studied. Clinical, genetic, laboratory, and pathology data were collected. Observations: A pathogenic DNA variant in COL4A3 was identified in 107 patients (35 families), whereas 133 harbored a pathogenic variant in COL4A4 (43 families). Digenic/complex inheritance was observed in 12 patients. Overall, the median kidney survival was 67 (95% CI, 58-73) years, without significant differences across sex (P = 0.8), causative genes (P = 0.6), or type of variant (P = 0.9). Microhematuria was the most common kidney manifestation (92.1%), and extrarenal features were rare. Findings on kidney biopsies ranged from normal to focal segmental glomerulosclerosis. The slope of estimated glomerular filtration rate change was -1.46 (-1.66 to -1.26) mL/min/1.73 m per year for the overall group, with no significant differences between ADAS genes (P = 0.2). Limitations: The relatively small size of this series from a single country, potentially limiting generalizability. Conclusions: Patients with ADAS have a wide spectrum of clinical presentations, ranging from asymptomatic to kidney failure, a pattern not clearly related to the causative gene or type of variant. The diversity of ADAS phenotypes contributes to its underdiagnosis in clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genetic kidney diseases as an underrecognized cause of chronic kidney disease, the key role of international registry reports

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Ars, Elisabet|||0000-0002-4118-4358
Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10-15% of cases of kidney replacement therapy (KRT) in adults. Paediatric nephrologists are very aware of the high prevalence of IKDs among their patients, but this is not the case for adult nephrologists. Recent publications have demonstrated that monogenic diseases account for a significant percentage of adult cases of CKD. A substantial number of these patients have received a non-specific/incorrect diagnosis or a diagnosis of CKD of unknown aetiology, which precludes correct treatment, follow-up and genetic counselling. There are a number of reasons why genetic kidney diseases are difficult to diagnose in adulthood: (i) adult nephrologists, in general, are not knowledgeable about IKDs; (ii) existence of atypical phenotypes; (iii) genetic testing is not universally available; (iv) family history is not always available or may be negative; (v) lack of knowledge of various genotype-phenotype relationships and (vi) conflicting interpretation of the pathogenicity of many sequence variants. Registries can contribute to visualize the burden of IKDs by regularly grouping all IKDs in their annual reports, as is done for glomerulonephritis or interstitial diseases, rather than reporting only cystic disease and hiding other IKDs under labels such as 'miscellaneous' or 'other'. Any effort to reduce the percentage of patients needing KRT with a diagnosis of 'nephropathy of unknown etiology' or an unspecific/incorrect diagnosis should be encouraged as a step towards precision nephrology. Genetic testing may be of value in this context but should not be used indiscriminately, but rather on the basis of a deep knowledge of IKDs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease

  • Furlano, Monica|||0000-0003-1025-3901
  • Ars, Elisabet|||0000-0002-4118-4358
  • Matamala Gastón, Ana María
  • Brossa Loidi, Vicens|||0000-0003-0403-6425
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Crespí, Jaume|||0000-0001-7564-2479
  • Roé Crespo, Esther|||0000-0003-1601-9227
  • Torra Balcells, Roser|||0000-0001-8714-2332
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants of the GLA gene. Heterozygous female patients may show much more variability in clinical manifestations, ranging from asymptomatic to full-blown disease. Because of this heterogeneous clinical picture in women, the diagnosis of FD has typically been delayed for more than a decade, and the optimal time to initiate treatment remains controversial. Case Presentation. Here, we present two unrelated female patients diagnosed with FD harbouring the same pathogenic GLA variant. We discuss the implications of initiating specific therapy at different stages of the disease, with and without organ involvement (early versus late therapeutic intervention). These clinical cases suggest that initiating specific treatment at an earlier age in women with FD may prevent organ involvement and associated clinical events.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autosomal dominant polycystic kidney disease in young adults

  • Martínez, Víctor
  • Furlano, Monica|||0000-0003-1025-3901
  • Sans, Laia
  • Pulido, Lissett
  • García, Rebeca|||0000-0003-0649-2766
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Sánchez-Rodríguez, Jinny
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Castro-Alonso, Cristina|||0000-0002-8363-1953
  • Fernández-Fresnedo, Gema
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Valenzuela, María Pau
  • Naranjo, Javier|||0000-0002-7004-6122
  • Martín Alemany, Nàdia|||0000-0002-4370-7562
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • González-Rodríguez, Juan David|||0000-0002-8863-2007
  • Panizo, Nayara|||0000-0002-1329-2976
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Fernández, Loreto
  • López, María Teresa
  • Dall'Anese, Cecilia
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Torra Balcells, Roser|||0000-0001-8714-2332
The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults. Family history, hypertension, albuminuria, estimated glomerular filtration rate (eGFR) and imaging tests were examined in 346 young adults (18-30 years old) out of 2521 patients in the Spanish ADPKD registry (REPQRAD). A literature review searched for reports on hypertension in series with more than 50 young (age <30 years) ADPKD patients. The mean age of this young adult cohort was 25.24 (SD 3.72) years. The mean age at diagnosis of hypertension was 21.15 (SD 4.62) years, while in the overall REPQRAD population was aged 37.6 years. The prevalence of hypertension was 28.03% and increased with age (18-24 years, 16.8%; 25-30 years, 36.8%). Although prevalence was lower in women than in men, the age at onset of hypertension (21 years) was similar in both sexes. Mean eGFR was 108 (SD 21) mL/min/1.73 m 2, 38.0% had liver cysts and 3.45% of those studied had intracranial aneurysms. In multivariate analyses, hematuria episodes and kidney length were independent predictors of hypertension (area under the curve 0.75). The prevalence of hypertension in 22 pediatric cohorts was 20%-40%, but no literature reports on hypertension in young ADPKD adults were found. Young adults present non-negligible ADPKD-related morbidity. This supports the need for a thorough assessment of young adults at risk of ADPKD that allows early diagnosis and treatment of hypertension.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Recomendaciones de manejo de la afectación renal en el complejo esclerosis tuberosa

  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Buj Pradilla, María José
  • Furlano, Monica|||0000-0003-1025-3901
  • Martínez, V.
  • Matamala, Anna|||0000-0002-1607-9011
  • Morales, M.
  • Robles, N.R.
  • Sans, Laia
  • Villacampa, F.
  • Torra Balcells, Roser|||0000-0001-8714-2332
El complejo esclerosis tuberosa (CET) es una enfermedad rara, hereditaria, multisistémica y con un amplio espectro fenotípico. Su manejo requiere de la colaboración de múltiples especialistas. Así como en la edad pediátrica cobra un especial relieve el neurólogo pediatra, en la edad adulta la afectación renal es la causante de la mayor morbimortalidad. Existen diversas recomendaciones sobre el manejo general del paciente con CET, pero ninguna que se centre en la afectación renal. Las presentes recomendaciones responden a la necesidad de proporcionar pautas para facilitar un mejor conocimiento y manejo diagnóstico-terapéutico de la afectación renal del CET mediante un uso racional de las pruebas complementarias y el empleo correcto de los tratamientos disponibles. Su elaboración se ha basado en el consenso dentro del grupo de trabajo de enfermedades renales hereditarias de la SEN/REDINREN. Ha contado con la participación de especialistas en CET no nefrólogos también con el fin de ampliar la visión de la enfermedad.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1

  • Olinger, Eric|||0000-0003-1178-7980
  • Hofmann, Patrick|||0000-0002-4586-641X
  • Kidd, Kendrah|||0000-0003-3771-0949
  • Dufour, Inès
  • Belge, Hendrica
  • Schaeffer, Céline|||0000-0001-5883-3951
  • Kipp, Anne
  • Bonny, Olivier
  • Deltas, Constantinos|||0000-0001-5549-9169
  • Demoulin, Nathalie|||0000-0002-3566-3950
  • Fehr, Thomas|||0000-0003-1668-1800
  • Fuster, D.G.|||0000-0001-7220-1803
  • Gale, Daniel|||0000-0002-9170-1579
  • Goffin, Eric|||0000-0001-9242-7148
  • Hodaňová, Kateřina|||0000-0001-9172-9945
  • Huynh-Do, Uyen|||0000-0002-7276-032X
  • Kistler, Andreas|||0000-0002-4114-9560
  • Morelle, Johann|||0000-0002-6925-1989
  • Papagregoriou, Gregory|||0000-0002-2440-9789
  • Pirson, Yves
  • Sandford, Richard
  • Sayer, John|||0000-0003-1881-3782
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Venzin, Christina
  • Venzin, Reto
  • Vogt, Bruno|||0000-0002-1548-6387
  • Živná, Martina
  • Greka, Anna|||0000-0001-5697-7791
  • Dahan, Karin
  • Rampoldi, Luca|||0000-0002-0544-7042
  • Kmoch, Stanislav
  • Bleyer, Anthony|||0000-0002-2804-5273
  • Devuyst, Olivier|||0000-0003-3744-4767
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is an increasingly recognized cause of end-stage kidney disease, primarily due to mutations in UMOD and MUC1. The lack of clinical recognition and the small size of cohorts have slowed the understanding of disease ontology and development of diagnostic algorithms. We analyzed two registries from Europe and the United States to define genetic and clinical characteristics of ADTKD-UMOD and ADTKD-MUC1 and develop a practical score to guide genetic testing. Our study encompassed 726 patients from 585 families with a presumptive diagnosis of ADTKD along with clinical, biochemical, genetic and radiologic data. Collectively, 106 different UMOD mutations were detected in 216/562 (38.4%) of families with ADTKD (303 patients), and 4 different MUC1 mutations in 72/205 (35.1%) of the families that are UMOD-negative (83 patients). The median kidney survival was significantly shorter in patients with ADTKD-MUC1 compared to ADTKD-UMOD (46 vs. 54 years, respectively), whereas the median gout-free survival was dramatically reduced in patients with ADTKD-UMOD compared to ADTKD-MUC1 (30 vs. 67 years, respectively). In contrast to patients with ADTKD-UMOD, patients with ADTKD-MUC1 had normal urinary excretion of uromodulin and distribution of uromodulin in tubular cells. A diagnostic algorithm based on a simple score coupled with urinary uromodulin measurements separated patients with ADTKD-UMOD from those with ADTKD-MUC1 with a sensitivity of 94.1%, a specificity of 74.3% and a positive predictive value of 84.2% for a UMOD mutation. Thus, ADTKD-UMOD is more frequently diagnosed than ADTKD-MUC1, ADTKD subtypes present with distinct clinical features, and a simple score coupled with urine uromodulin measurements may help prioritizing genetic testing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correction, The 2019 and 2021 International workshops on Alport syndrome

  • Daga, Sergio
  • Ding, Jie
  • Deltas, Constantinos|||0000-0001-5549-9169
  • Savige, Judy|||0000-0002-6813-0288
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Hoefele, Julia|||0000-0002-7917-7129
  • Flinter, Frances
  • Gale, Daniel|||0000-0002-9170-1579
  • Aksenova, Marina|||0000-0002-3699-1884
  • Kai, Hirofumi
  • Perin, Laura
  • Barua, Moumita
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Miner, Jeff H.|||0000-0002-1510-8714
  • Massella, Laura|||0000-0001-5796-3965
  • Ljubanović, Danica Galešić
  • Lennon, Rachel|||0000-0001-6400-0227
  • Weinstock, Andrè B.
  • Knebelmann, Bertrand
  • Cerkauskaite, Agne
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Turner, A. Neil|||0000-0003-4547-873X
  • Baldassarri, Margherita
  • Pinto, Anna Maria|||0000-0001-6259-6901
  • Renieri, Alessandra|||0000-0002-0846-9220